Alan K Davis
Overview
Explore the profile of Alan K Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1619
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xin Y, Griffiths R, Davis A
J Psychoactive Drugs
. 2025 Feb;
:1-8.
PMID: 39943916
An interesting aspect of entity encounters during psychedelic experiences is their ability to transform one's religious beliefs. However, little is known about sex differences in these transformations. This study investigates...
2.
Mian M, Horan J, Hunter T, Davis A, Armstrong S
Soc Work
. 2025 Feb;
PMID: 39935253
Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adolescents-require further understanding. Social workers will likely play a crucial role...
3.
Hyzak K, Bunger A, Bogner J, Davis A
J Head Trauma Rehabil
. 2024 Sep;
39(6):458-471.
PMID: 39330949
Objective: Identify barriers to the adoption of the Ohio State University Traumatic Brain Injury Identification Method (OSU TBI-ID) in behavioral healthcare organizations and match these barriers to implementation strategies to...
4.
Armstrong S, Davis A
Science
. 2024 Sep;
385(6715):1255.
PMID: 39298596
There is an urgent need to develop better treatments for mental health conditions that affect one in every eight people in the world. To combat this concern, psychedelic drugs have...
5.
Davis A, Bates M, Lund E, Sepeda N, Levin A, Armstrong S, et al.
J Psychoactive Drugs
. 2024 Sep;
:1-14.
PMID: 39263894
We sought to identify patterns of psychedelic use among United States military veterans, compare demographic variables and perspectives of those who did and did not report use, and characterize benefits...
6.
Levin A, Lancelotta R, Sepeda N, Gukasyan N, Nayak S, Wagener T, et al.
PLoS One
. 2024 Mar;
19(3):e0300501.
PMID: 38483940
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin...
7.
Davis A, Arterberry B, Xin Y, Agin-Liebes G, Schwarting C, Williams M
Front Epidemiol
. 2024 Mar;
2:876706.
PMID: 38455323
Background: The current study is one of the first to examine race, ethnic, and sex differences in the prevalence of and trends in hallucinogen use among lifetime users in the...
8.
Armstrong S, Xin Y, Sepeda N, Polanco M, Averill L, Davis A
Mil Psychol
. 2024 Feb;
36(2):184-191.
PMID: 38377244
This study evaluated prospective associations of ibogaine and 5-MeO-DMT treatment for risky alcohol use and post-traumatic stress disorder (PTSD) symptoms among United States (US) Special Operations Forces Veterans (SOFV). Data...
9.
Aday J, Bloesch E, Davis A, Domoff S, Scherr K, Woolley J, et al.
J Psychoactive Drugs
. 2024 Feb;
:1-10.
PMID: 38310541
Qualitative studies and anecdotal reports suggest that experiences with ayahuasca, a psychedelic brew found in Central and South America, may be followed by individuals enduringly feeling more grateful and connected...
10.
Davis A, Arterberry B, Xin Y, Hubbard S, Schwarting C, Bonar E
Cannabis
. 2023 Nov;
6(3):105-126.
PMID: 38035170
Introduction: We examined whether the Dualistic Model of Passion (DMP; i.e., obsessive passion [OP] and harmonious passion [HP]) for cannabis use was prospectively associated with cannabis use and use-related outcomes,...